Novo Nordisk News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.06.24	Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma (Benzinga)
27.06.24	Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand (Benzinga)
27.06.24	Hohe Belastung für Novo Nordisk: Nierenerkrankungs-Medikament in Studie nicht erfolgreich (Dow Jones) Novo Nordisk hat einen Studienrückschlag mit einem Medikament zur Behandlung von Patienten mit chronischer Nierenerkrankung erlitten.» mehr
26.06.24	Novo Nordisk Discontinues Ocedurenone Trial, To Record Impairment Loss (RTTNews)
26.06.24	Novo Nordisk Halts Late-Stage Study Of Experimental Hypertension Drug, Takes Over $800M Impairment Charge (Benzinga)
26.06.24	Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
25.06.24	MÄRKTE EUROPA/Airbus belastet DAX - OMX profitiert vom Abnehmhype (Dow Jones)
25.06.24	Why Novo Nordisk Shares Are Trading Higher Tuesday (Benzinga)
25.06.24	MÄRKTE EUROPA/Airbus belastet den DAX - OMX profitiert vom Abnehmhype (Dow Jones)
25.06.24	Novo Nordisk gains approval to sell weight-loss drug Wegovy in China (MarketWatch)
25.06.24	Abnehm-Medikament Wegovy von Novo Nordisk in China zugelassen (Dow Jones)
25.06.24	Novo Nordisk weight loss drug Wegovy approved in China (Financial Times)
25.06.24	Novo Nordisk Surges Nearly 3% After Weight Loss Drug Wegovy Wins Approval in China (Benzinga)
25.06.24	Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply (RTTNews)
25.06.24	Wegovy, Ozempic Maker Novo Nordisk To Invest $4.1B In US Manufacturing, Doubling Plant Size To Meet Surging Demand For Weight Loss Drugs (Benzinga)
25.06.24	Novo Nordisk investiert 4,1 Milliarden US-Dollar in neues US-Werk (Dow Jones)
24.06.24	Study Says Wegovy Induces Higher Weight Loss In Women Than Men (RTTNews)
24.06.24	Ozempic maker Novo Nordisk to spend $4.1 billion to boost production (MarketWatch)
24.06.24	Novo Nordisk invests $4bn to expand weight loss drug production in US (Financial Times)
24.06.24	Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely' (Benzinga)
24.06.24	Novo Nordisk Reports Superiority Of Mim8 Prophylaxis In Hemophilia A Trial (RTTNews)
21.06.24	MÄRKTE EUROPA/Schwach nach Verfall - Tech- und Bankwerte belasten (Dow Jones)
21.06.24	The Best Could Be Yet to Come for Novo Nordisk and Ozempic (MotleyFool)
17.06.24	Novo Nordisk CEO Agrees To Testify In US Senate Hearing Over Ozempic, Wegovy Prices (RTTNews)
13.06.24	Novo Nordisk Unusual Options Activity For June 13 (Benzinga)
12.06.24	Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report (Benzinga)
10.06.24	6 Analysts Have This To Say About Novo Nordisk (Benzinga)
06.06.24	Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again (MotleyFool)
06.06.24	Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market (Benzinga)
04.06.24	Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock (MotleyFool)
03.06.24	$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today (Benzinga)
01.06.24	This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors (MotleyFool)
31.05.24	Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes (Benzinga)
30.05.24	New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk (Benzinga)
30.05.24	Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs (Benzinga)
29.05.24	Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply (Benzinga)
28.05.24	Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System (Benzinga)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	76.62	0.39 %	K V
Part Grp Hldg	1’271.50	0.36 %	K V
Holcim	89.08	0.25 %	K V
Logitech Intl	74.82	-0.05 %	K V
Lonza Grp	540.60	-0.15 %	K V
UBS Group	27.82	-1.24 %	K V
Sika	223.10	-1.37 %	K V
Nestle	74.10	-1.49 %	K V
Swiss Re	129.60	-1.78 %	K V
Givaudan	3’961.00	-2.46 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Novo Nordisk (spons. ADRs)

Aktien Top/Flop

Novo Nordisk Peer Group Nachrichten

Meistgelesene Nachrichten